Dr. Z. Dave Sharp's lab explores novel strategies to prevent diseases while
mitigating morbidities associated with aging, thereby reducing suffering and
looming economic burden.
They study how chronic mTOR inhibition
prevents, delays, and/or reduces the severity of cancer while mitigating other
negative effects of aging.
Their experiments show this
is possible with a novel enteric formulation of rapamycin, eRapa. Their current
research goals aim to understand the mechanism of action of eRapa in the
prevention of colon cancer using mouse models combined with genetic, epigenetic
and protein synthesis profiling technologies.
Christy B, Demaria, M, Campisi, J, Huang, J, Jones, D, Dodds, SG, Williams, C, Hubbard, G, Livi, CB, Gao, X, Weintraub, S. Curiel, T, Sharp, ZD, Hasty, P. (2015) p53 and rapamycin are additive. Oncotarget. 6(18), 15802-15813 PMID: 26158292 (Note: This was published as a Priority Paper)
Dodds SG., Livi, CB, Parihar, M, Hsu, H-K, Benevides, AD, Morris, J, Javors, M, Strong, R, Christy, B, Sharp, ZD. (2016) Adaptations to chronic rapamycin in mice. Pathobiology of Aging and Age Related Diseases 6:31688 10.3402/pba.v6.31688 PMID: 27237224
Complete List of Published Works in MyBibliography: